CRESCENT BIOPHARMA

Company snapshot

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. Crescent’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies e

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CRESCENT BIOPHARMA. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CRESCENT BIOPHARMA.

1. Jun 8, 2026 Clinical update

   Folic acid — Unknown

2. Jun 8, 2026 Clinical update

   Chlorhexidine — Approved

3. May 23, 2026 Clinical update

   CR-001 — Phase 2

4. Nov 12, 2024 Patent grant

   Antiviral use of FABP4 modulating compounds

5. Sep 10, 2024 Patent grant

   Cell metabolism modulating compounds and uses thereof

View all clinical trial activity →

• What is CRESCENT BIOPHARMA?

  CRESCENT BIOPHARMA is a biotech organization headquartered in Waltham, USA. It trades on NYSE under ticker CBIO. Primary therapeutic focus areas include Neonatal Infections, Locally Advanced / Metastatic Solid Tumors, Acute Myocardial Infarction. NovaPharmaNews links 3 clinical p

• Is CRESCENT BIOPHARMA publicly traded?

  Yes. CRESCENT BIOPHARMA is listed with ticker CBIO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does CRESCENT BIOPHARMA develop or market?

  We link 5 drug profile(s) where CRESCENT BIOPHARMA is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/crescent-biopharma-inc#company-drugs.

• What are the latest developments for CRESCENT BIOPHARMA?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CRESCENT BIOPHARMA focus on?

  CRESCENT BIOPHARMA focuses on Neonatal Infections, Locally Advanced / Metastatic Solid Tumors, Acute Myocardial Infarction based on our analysis of their pipeline programs and drug development activities.